AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $1.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$1.2M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 5 added, 0 cutMore adding
Key stats
Fundamentals Sep 30- Open
- $35.98
- 52-wk high
- $42.50
- High
- $36.19
- 52-wk low
- $15.25
- Low
- $35.52
- Prev close
- $36.13
- Mkt cap
- $26.36B
- Volume
- 6.76M
- Beta
- 1.12
- P/S
- 3500.4x
- P/B
- 6.3x
- Profit margin
- +0.0%
- Op margin
- -25408.0%
- ROE
- -8.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about ROIV filings
Are insiders buying or selling Roivant Sciences Ltd (ROIV) stock?
Net selling: insiders sold $1.2M and bought $0 of ROIV stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $1.2M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Fitzgerald, Meghan (Director), who sold $1M. The latest filing was on Sep 17, 2026.
Which members of Congress have traded ROIV recently?
None. No member of Congress disclosed a ROIV trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this ROIV smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
What insiders are doing
How top traders are positioned
No tracked top-trader positions in ROIV right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings landed in line with what analysts expected.
Earnings per share
-$0.45 expected
Revenue
$2.3M expected
Company GAAP EPS
From the company's release
Compared on the analyst basis, which counts earnings differently from the company.
Reports Nov 9, 2026, in 39 days
Estimates as of Sep 30, 2026
EPS expected
-$0.59 to -$0.35
Revenue expected
11 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.6M | $2.0M | $2.5M | $1.4M |
| Cost of what it sold | $111.0K | $700.0K | $320.0K | $284.0K |
| Gross profit | $1.5M | $1.3M | $2.2M | $1.2M |
| What it spent | ||||
| Research and development | $164.6M | $165.4M | $198.9M | $202.0M |
| Sales and admin | $143.1M | $175.1M | $158.3M | $165.5M |
| Total operating expenses | $307.7M | $340.5M | $357.2M | $367.2M |
| What was left | ||||
| Operating profit | -$306.2M | -$339.2M | -$355.0M | -$366.0M |
| Profit before tax | -$159.0M | -$290.4M | $454.1M | -$294.6M |
| Tax | $7.0M | $23.3M | $98.4M | -$4.0M |
| Net profit | -$113.5M | -$265.9M | $303.0M | -$189.8M |
| EBITDA | -$158.1M | -$289.7M | $454.7M | -$288.3M |
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
40 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace